EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY 4.0

Anticoagulant versus Antiplatelet Therapy After Acute Coronary Syndromes in Patients with Coronary Artery Ectasia: A Retrospective Cohort Study

Fabio Solis-Jiménez iD, Ximena Latapi-Ruiz Esparza iD, Hannah Priscila Guzman-Solorzano iD, Monserrat Villalobos-Pedroza iD, Luis Angel Morales-Villamil iD, Braiana Angeles Diaz-Herrera iD, Sarai Hernandez-Pastrana iD, Rodrigo Gopar-Nieto iD, Eduardo A Arias-Sanchez iD, Luis Alfonso Marroquín-Donday iD, Gian Manuel Jiménez-Rodríguez iD, Daniel Sierra-Lara iD und 2 weitere

Cardiovascular Drugs and Therapy · 2026-06 · 40 (3) · 1021-1033

DOI: 10.1007/s10557-025-07784-0 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 24.09.2025. Verfasst von Fabio Solis-Jiménez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Universidad Nacional Autónoma de México, Mexico City, Mexico. fabio_jimenez@comunidad.unam.mx. Hauptthemen laut MEDLINE: Anticoagulants, Platelet Aggregation Inhibitors, Acute Coronary Syndrome, Dual Anti-Platelet Therapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Patients with coronary ectasia (CAE) have an increased risk of major cardiovascular events (MACE). Current preventive treatments are uncertain, with oral anticoagulants often prescribed based on limited retrospective studies. Our aim is to help address the question: what is the most appropriate treatment?

Methods

Using a retrospective cohort of patients with an ACS and CAE in a single center in Mexico City, two groups were observed based on the treatment at discharge: dual antiplatelet therapy (group 1) and anticoagulation with either a VKA or a DOAC, regardless of antiplatelet therapy (group 2). The main outcome was MACE, which was a composite of all-cause mortality, reinfarction, and ischemic stroke at 4.5 years follow-up.

Results

A total of 354 patients admitted for ACS and CAE were included. 228 (64.4%) patients were classified in the DAPT group and 126 (35.5%) in the anticoagulants group. The DAPT group had higher type 2 diabetes rates, NSTEMI presentation, and lower-grade ectasia. The anticoagulation group had higher STEMI presentation and higher-grade ectasia. The DAPT group had 33 (14.5%) events of MACE, whereas the anticoagulation group had 16 (13.1%) events. Anticoagulants were not associated with a risk reduction of the primary endpoint (HR 0.95; 95% CI, 0.47–1.54; p = 0.59), nor any of the individual components.

Conclusion

This retrospective cohort study showed similar effectiveness between DAPT and anticoagulation in patients with ACS and CAE for preventing MACE, and lower bleeding risk. Further research is needed to identify optimal candidates for each antithrombotic regime. Graphical Abstract DAPT: double antiplatelet therapy, HR: hazard ratio

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsPlatelet Aggregation InhibitorsAcute Coronary SyndromeDual Anti-Platelet TherapyHumansRetrospective StudiesFemaleMaleAgedMiddle AgedRisk FactorsTreatment OutcomeDilatation, PathologicRisk AssessmentTime Factors

Stichwörter der Autor:innen

Acute coronary syndromesAnticoagulationAntithrombotic therapyCoronary artery ectasiaDAPTMyocardial infarction

Substanzen

AnticoagulantsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Universidad Nacional Autónoma de México, Mexico City, Mexico. fabio_jimenez@comunidad.unam.mx.
  • Interventional Cardiology Department, Instituto Nacional de Cardiologia Ignacio Chávez, Mexico City, Mexico. fabio_jimenez@comunidad.unam.mx.
  • Coronary Care Unit Department, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
  • Facultad de Medicina de la Universidad de Colima, Colima, Mexico.
  • Interventional Cardiology Department, Instituto Nacional de Cardiologia Ignacio Chávez, Mexico City, Mexico.
  • Benemerita Universidad Autonoma de Puebla, Puebla, Mexico.

ORCID-Profile: Fabio Solis-Jiménez, Ximena Latapi-Ruiz Esparza, Hannah Priscila Guzman-Solorzano, Monserrat Villalobos-Pedroza, Luis Angel Morales-Villamil, Braiana Angeles Diaz-Herrera, Sarai Hernandez-Pastrana, Rodrigo Gopar-Nieto, Eduardo A Arias-Sanchez, Luis Alfonso Marroquín-Donday, Gian Manuel Jiménez-Rodríguez, Daniel Sierra-Lara, Diego Araiza-Garaygordobil, Alexandra Arias-Mendoza

Zitieren

APA

Solis-Jiménez, F., Esparza, X. L., Guzman-Solorzano, H. P., Villalobos-Pedroza, M., Morales-Villamil, L. A., Diaz-Herrera, B. A., Hernandez-Pastrana, S., Gopar-Nieto, R., Arias-Sanchez, E. A., Marroquín-Donday, L. A., Jiménez-Rodríguez, G. M., Sierra-Lara, D., Araiza-Garaygordobil, D., & Arias-Mendoza, A. (2026). Anticoagulant versus Antiplatelet Therapy After Acute Coronary Syndromes in Patients with Coronary Artery Ectasia: A Retrospective Cohort Study. Cardiovascular Drugs and Therapy, 40(3), 1021-1033. https://doi.org/10.1007/s10557-025-07784-0

Vancouver

Solis-Jiménez F, Esparza XL, Guzman-Solorzano HP, Villalobos-Pedroza M, Morales-Villamil LA, Diaz-Herrera BA, et al. Anticoagulant versus Antiplatelet Therapy After Acute Coronary Syndromes in Patients with Coronary Artery Ectasia: A Retrospective Cohort Study. Cardiovascular Drugs and Therapy. 2026;40(3):1021-1033. doi:10.1007/s10557-025-07784-0

BibTeX
@article{SolisJimnez2026,
  author = {Solis-Jiménez, Fabio and Esparza, Ximena Latapi-Ruiz and Guzman-Solorzano, Hannah Priscila and Villalobos-Pedroza, Monserrat and Morales-Villamil, Luis Angel and Diaz-Herrera, Braiana Angeles and Hernandez-Pastrana, Sarai and Gopar-Nieto, Rodrigo and Arias-Sanchez, Eduardo A and Marroquín-Donday, Luis Alfonso and Jiménez-Rodríguez, Gian Manuel and Sierra-Lara, Daniel and Araiza-Garaygordobil, Diego and Arias-Mendoza, Alexandra},
  title = {Anticoagulant versus Antiplatelet Therapy After Acute Coronary Syndromes in Patients with Coronary Artery Ectasia: A Retrospective Cohort Study},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2026},
  volume = {40},
  number = {3},
  pages = {1021--1033},
  doi = {10.1007/s10557-025-07784-0}
}
Kostenlos starten →